Glaukos has entered a research and development collaboration agreement with D. Western Therapeutics Institute to develop novel intraocular products for the treatment of glaucoma, the company announced in a press release.
Products will be developed from DWTI’s ROCK inhibitor compound library, while Glaukos will conduct the evaluation and development of those compounds, the release said.
Glaukos will pay DWTI an upfront technology access fee and research support fees, and if one or more candidate compounds are found, Glaukos will hold exclusive rights to develop intracameral and topical
Uncategorized